Eric Olson is a Psychiatry physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3000 N Garfield St Ste 105
Midland, TX 797056417
Telephone
432-620-0161Registry record last updated 21 Sept 2010.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ITI, Inc.Program year20211 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
93.7%Benzodiazepine16.2%Clonazepam36%Alprazolam31%Lorazepam30%Temazepam3%Part D<11 patientsSNRI13.2%Venlafaxine Hcl Er64%Desvenlafaxine Succinate Er22%Duloxetine Hcl10%Fetzima5%Part D<11 patients+ 25 more classes in this area
Cardiovascular
2.3%Beta blocker1.9%Atenolol38%Propranolol Hcl36%Propranolol Hcl Er26%Part D<11 patientsPeroxisome Proliferator-activated Receptor alpha Agonist0.4%Fenofibrate100%Part D<11 patientsHormonal (systemic)
1.6%l-Thyroxine0.7%Levothyroxine Sodium100%Part D<11 patientsl-Triiodothyronine0.5%Liothyronine Sodium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
25 NIH research awards on record, funded 1989–2026 per NIH RePORTER. The latest:
- The role of nuclear envelope protein NET39 in skeletal muscle function and diseases
Ut Southwestern Medical Center
FY2026$445,588R01AR080676 - Transcriptional Control of Neonatal Heart Regeneration
Ut Southwestern Medical Center
FY2025$565,036R01HL157281 - The role of nuclear envelope protein NET39 in skeletal muscle function and diseases
Ut Southwestern Medical Center
FY2025$422,136R01AR080676
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”